Dyne Pharma - Total Utang marang Modal DYN

Dyne Pharma - logo grafis emiten DYN

Dyne Therapeutics, Inc. (DYN) is developing innovative drugs to combat muscle pathologies, attracting leading oligonucleotide experts with generous stock options. This chart of the debt-to-equity market trend reflects 0.31. The business strategy relies on diversifying genetic research to meet latent demand, while strong management focuses on passing regulatory reviews and expanding clinical trials.

Dyne Therapeutics (DYN): Rasio Kabeh Utang marang Dana Pribadi saka 04.07.2022 nganti 30.10.2026

Rincian analitis lan laporan data perusahaan Dyne Corp (DYN)

- rega saham lan konsensus proyeksi valuasi:
Rega saham Dyne Therapeutics|DYN - Konsensus nilai wajar
- rincian nilai pasar emiten:
Kapitalisasi pasar Dyne Therapeutics|DYN - Nilai Perusahaan
- indikator kapitalisasi buku:
Aset Bersih saben Siji Saham Dyne Therapeutics|DYN - Nilai Akuntansi Perusahaan|Rasio Nilai Pasar marang Nilai Buku dyne-tx.com|DYN - Gunggung Aset Perusahaan
- rincian utang lan likuiditas:
Total Utang marang Modal Dyne Therapeutics, Inc.|DYN - Utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Dyne Therapeutics, Inc.|DYN - Kewajiban utang agregat|Rasio utang marang kapitalisasi buku Dyne Therapeutics|DYN - Tanggungan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Dyne Therapeutics|Indikator likuiditas cepet dyne-tx.com
- data bathi resik lan rasio valuasi:
DYN - Bathi resik
Pambiji fundamental perusahaan:DYN, Dyne Therapeutics
Produk dadi dyne-tx.com

Dyne Therapeutics, Inc. (DYN) minimizes scientific risks by developing innovative genetic therapies for rare muscle pathologies to capture untapped market niches. An analysis of the financial stability ratio (debt-to-equity) allows for an assessment of the proportion of borrowed funds to equity assets, where excessive leverage signals liquidity risk, while minimal leverage indicates insufficient business scaling.

Perusahaan pesaing

JAZZ (Jazz Pharmaceuticals plc) - Total Utang marang Modal|CYTK: Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal PTCT|Total Utang marang Modal Scholar Rock Inc. (SRRK)|Utang marang Ekuitas Centessa Pharmaceuticals CNTA|Rasio Kabeh Utang marang Dana Pribadi EWTX|RAPP - Utang marang Ekuitas|Alumis Inc (ALMS) - Rasio Total Utang marang Ekuitas|ZVRA: Total Utang marang Modal|Contineum Corp (CTNM) - Total Utang marang Modal|Rasio Total Utang marang Ekuitas LRMR|CAPR: Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas Entrada Therapeutics, Inc. (TRDA)|Channel Therapeutics Inc. - Rasio Utang marang Ekuitas|Total Utang marang Modal MNOV (MediciNova)|Serina Pharma (SER) - Utang marang Modal|BTAI: Rasio Total Utang marang Ekuitas|PMN - Total Utang marang Modal|apimedsus.com (APUS) - Utang marang Ekuitas|AEON Biopharma, Inc. - Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas NLS Pharmaceutics Ltd.|Utang marang Modal Bionomics Ltd BNOX|Utang marang Ekuitas FSD Pharma (HUGE)|Utang marang Ekuitas RETA (reatapharma.com)